California State Teachers Retirement System Increases Stake in Krystal Biotech, Inc. $KRYS

California State Teachers Retirement System boosted its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 27.2% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 26,186 shares of the company’s stock after acquiring an additional 5,603 shares during the period. California State Teachers Retirement System’s holdings in Krystal Biotech were worth $6,764,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in KRYS. Avoro Capital Advisors LLC raised its position in shares of Krystal Biotech by 4.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,888,888 shares of the company’s stock valued at $712,226,000 after purchasing an additional 111,111 shares during the period. State Street Corp lifted its stake in shares of Krystal Biotech by 10.5% during the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company’s stock valued at $186,306,000 after buying an additional 128,639 shares in the last quarter. Soleus Capital Management L.P. grew its stake in Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after buying an additional 481,200 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Krystal Biotech by 5.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 533,964 shares of the company’s stock valued at $94,261,000 after buying an additional 28,075 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Krystal Biotech by 13.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 529,955 shares of the company’s stock valued at $130,656,000 after acquiring an additional 62,897 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Stock Up 0.3%

Shares of KRYS stock opened at $325.78 on Thursday. The business has a 50-day moving average price of $340.79 and a two-hundred day moving average price of $297.13. Krystal Biotech, Inc. has a 12-month low of $132.31 and a 12-month high of $382.54. The firm has a market cap of $9.64 billion, a P/E ratio of 40.82 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. As a group, research analysts expect that Krystal Biotech, Inc. will post 7.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on KRYS shares. TD Cowen increased their target price on Krystal Biotech from $306.00 to $403.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Evercore reiterated an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 5th. Bank of America increased their price objective on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Wall Street Zen lowered Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Weiss Ratings upgraded Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech presently has an average rating of “Moderate Buy” and an average price target of $361.56.

Insider Transactions at Krystal Biotech

In related news, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the sale, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares in the company, valued at $424,623,337.05. The trade was a 1.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock worth $8,243,923 over the last ninety days. Insiders own 13.10% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.